Tokio Marine Asset Management Co. Ltd. Sells 1,117 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tokio Marine Asset Management Co. Ltd. trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,575 shares of the medical equipment provider’s stock after selling 1,117 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Zimmer Biomet were worth $678,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. GAMMA Investing LLC bought a new position in Zimmer Biomet in the fourth quarter worth about $65,000. Community Bank & Trust Waco Texas raised its stake in Zimmer Biomet by 60.6% in the fourth quarter. Community Bank & Trust Waco Texas now owns 5,736 shares of the medical equipment provider’s stock worth $698,000 after buying an additional 2,164 shares in the last quarter. Wedge Capital Management L L P NC raised its stake in Zimmer Biomet by 3.3% in the fourth quarter. Wedge Capital Management L L P NC now owns 123,822 shares of the medical equipment provider’s stock worth $15,069,000 after buying an additional 4,000 shares in the last quarter. RWA Wealth Partners LLC bought a new position in Zimmer Biomet in the fourth quarter worth about $375,000. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Zimmer Biomet by 1.9% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 18,859 shares of the medical equipment provider’s stock worth $2,295,000 after buying an additional 344 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Down 0.3 %

Shares of Zimmer Biomet stock opened at $119.35 on Friday. The company’s fifty day simple moving average is $125.98 and its 200-day simple moving average is $119.52. The stock has a market capitalization of $24.52 billion, a PE ratio of 24.41, a P/E/G ratio of 2.20 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $149.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.88 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is 19.63%.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.95% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of research reports. Truist Financial increased their price target on shares of Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a research note on Friday, February 23rd. TheStreet raised shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 9th. Finally, Evercore ISI raised their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.